Dysglycaemia in cardiovascular disease: what's the best glycaemic risk predictor? [0.03%]
心血管疾病的糖代谢异常：何种血糖风险预测指标更佳？
Stefano Del Prato
Stefano Del Prato
Dysglycaemia screening and its prognostic impact in patients with coronary artery disease: experiences from the EUROASPIRE IV and V cohort studies [0.03%]
冠心病患者的糖尿病筛查及其预后影响：来自EUROASPIRE IV和V队列研究的经验
Giulia Ferrannini,Jaakko Tuomilehto,Guy De Backer et al.
Giulia Ferrannini et al.
Background: Glucose perturbations can be detected by fasting plasma glucose (FPG), HbA1c, and the oral glucose tolerance test (OGTT). The highest yield is provided by OGTT. HbA1c is considered more practical. We compare t...
The Lancet Diabetes Endocrinology
The Lancet Diabetes Endocrinology
Muscle matters: the effects of medically induced weight loss on skeletal muscle [0.03%]
肌肉重量损失对骨骼肌的影响
Carla M Prado,Stuart M Phillips,M Cristina Gonzalez et al.
Carla M Prado et al.
Sodium-glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials [0.03%]
钠葡萄糖协同转运蛋白2抑制剂治疗住院COVID-19患者的疗效：随机试验的前瞻性荟萃分析
Claire Vale,Peter J Godolphin,David Fisher et al.
Claire Vale et al.
Background: Sodium-glucose co-transporter-2 (SGLT2) inhibitors have been proposed as a potential treatment for adults hospitalised with COVID-19, due to their potential anti-inflammatory and endothelial protective effects...
Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial [0.03%]
SGLT2抑制剂对COVID-19住院患者无需器官支持的生存效果（ACTIV-4a）：一项实用性的多中心开放标签随机对照平台试验
Mikhail N Kosiborod,Sheryl L Windsor,Orly Vardeny et al.
Mikhail N Kosiborod et al.
Background: Patients hospitalised for COVID-19 are at risk for multiorgan failure and death. Sodium-glucose co-transporter-2 (SGLT2) inhibitors provide cardiovascular and kidney protection in patients with cardiometabolic...
Randomized Controlled Trial
The lancet. Diabetes & endocrinology. 2024 Oct;12(10):725-734. DOI:10.1016/S2213-8587(24)00218-3 2024
Islet-after-kidney transplantation versus kidney alone in kidney transplant recipients with type 1 diabetes (KAIAK): a population-based target trial emulation in France [0.03%]
法国肾脏移植受者中1型糖尿病患者胰岛-肾脏联合移植与单独肾脏移植的比较（KAIAK）：基于人群的目标试验模拟研究
Mehdi Maanaoui,Rémi Lenain,Yohann Foucher et al.
Mehdi Maanaoui et al.
Background: Islet transplantation has been associated with better metabolic control and quality of life than insulin treatment alone, but direct evidence of its effect on hard clinical endpoints is scarce. We aimed to ass...
Islet transplantation in kidney transplant recipients with type 1 diabetes [0.03%]
肾脏移植受者的1型糖尿病患者的胰岛移植手术
Shareen Forbes,Thomas W H Kay
Shareen Forbes